Biocartis Completes ?34,5 Million ($44,5 Million) Series D Fund Raising

Lausanne, Switzerland (ots/PRNewswire) - – Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms – Strong support from internal shareholders and a recognition of our achievements Biocartis, a molecular diagnostics company developing and commercializing innovative, high quality, easy to use platforms and clinically […]